Skip to main content
. Author manuscript; available in PMC: 2018 Dec 15.
Published in final edited form as: Biol Psychiatry. 2017 Jul 4;82(12):866–874. doi: 10.1016/j.biopsych.2017.06.024

Figure 2. Significant interaction effect of rs110402 and childhood abuse on percent change PSS-SR score.

Figure 2

The boxplots describe the mean percent change of PSS total score in abused and non-abused patients treated with the GSK561679 or placebo. GG carriers are shown in light grey and AA/AG in dark grey. Higher PSS percent change corresponds to improvement (reduction) in PTSD symptoms from baseline to endpoint. rs110402 A carrier status by childhood abuse exposure showed a significant interaction effect on PSS score percent change over treatment in subjects treated with GSK561679 (s=-1.904, p=0.043) but not in subjects treated with placebo (s=0.421, p=0.68). rs110402 GG carriers exposed to child abuse displayed the highest percent change of PSS symptoms following GSK561679 treatment. PSS-SR, PTSD Symptom Scale, Self-Report